Presentation (CTI)

OBJECTIVES: Vasomotor symptoms (VMS) associated with menopause are frequent, persistent, and reduce quality-of-life (QoL), with limited non-hormonal treatment options available. This analysis estimated EQ-5D-3L health state utility values associated with VMS, overall and in women with ≤1 year since menopause (≤1 year since amenorrhea), representing women at an earlier stage of symptom onset, to quantify the utility burden and subsequent improvement linked to at least 50% reduction in the frequency of moderate-to-severe VMS.
METHODS: This is a post-hoc analysis using data from the OASIS-1/2 trials (NCT05042362; NCT05099159) of elinzanetant versus placebo. EQ-5D-3L index (UK tariff, mapped from EQ-5D-5L using Hernández Alava et al. (2023)) [a standardized measure of health-related QoL anchored at 0 (death) and 1 (perfect health)] was modelled using mixed model repeated measures with a time-dependent covariate for VMS response (≥50% reduction in moderate-to-severe hot flash frequency; yes/no). Subgroup analyses in women ≤1 year since menopause were conducted by including a subgroup-by-response interaction.
RESULTS: 796 patients were included in the analysis, with 117 women ≤1 year since menopause; at baseline, mean utility was 0.820 overall and 0.810 within the subgroup. In the overall population, EQ-5D-5L was significantly associated with VMS response (yes: 0.854) vs. no: 0.831; difference 0.024, p<0.001). When including a subgroup by VMS response interaction, the magnitude of this difference by response status was higher among women ≤1 year since menopause (yes: 0.868 vs no: 0.816; difference 0.052, interaction p=0.001).
CONCLUSIONS: VMS have measurable impact on QoL. Decreasing the frequency of VMS is associated with a utility improvement. Women experiencing symptoms close to the start of menopause have lower baseline utility values and experience a pronounced utility improvement with elinzanetant treatment, suggesting a benefit in addressing symptoms early.